Literature DB >> 2785226

Antibody to a cryptic, solid phase C1Q antigen in membranoproliferative nephritis.

C F Strife1, A E Leahy, C D West.   

Abstract

IgG containing material detected in membranoproliferative nephritis (MPGN) serum with a solid phase (sp) Clq ELISA has been presumed to be immune complexes. However, in serum from 13 MPGN patients containing large amounts of spClq-binding material, sucrose density ultracentrifugation and sieve chromatography showed spClq-binding protein to sediment at 7S or cofractionate with IgG. One serum (stored for 12 years) contained, in addition, spClq-binding material sedimenting at more than 19S. Isolated MPGN IgG was shown to bind to spClq. SpClq-binding material could be totally removed from MPGN serum by absorption with BSA-anti-BSA immune precipitates, and by acid elution of the precipitates IgG binding to spClq could be recovered. F(ab')2, isolated from pepsin digested MPGN IgG, continued to bind spClq. Binding of MPGN IgG or F(ab')2 to spClq was not inhibited by 2 M NaCl. Incubation of MPGN serum with 125I Clq followed by sucrose density ultracentrifugation resulted in a peak of radioactivity at 11S, the sedimentation rate of Clq, giving evidence that material binding fluid phase Clq is not present. SpClq-binding IgG was detected in 54% of 68 MPGN patients. These results indicate that the 7S spClq-binding IgG represents antibody to a cryptic antigen revealed only when Clq fixes to a solid surface.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785226     DOI: 10.1038/ki.1989.61

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

Review 1.  Autoantibodies against C1q: view on clinical relevance and pathogenic role.

Authors:  C E Siegert; M D Kazatchkine; A Sjöholm; R Würzner; M Loos; M R Daha
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Defective prevention of immune precipitation in autoimmune diseases is independent of C4A*Q0.

Authors:  G J Arason; R Kolka; A B Hreidarsson; H Gudjonsson; P M Schneider; L Fry; A Arnason
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

3.  Antibodies against C1q in anti-glomerular basement membrane nephritis.

Authors:  I E Coremans; M R Daha; E A van der Voort; Y Muizert; C Halma; F C Breedveld
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

4.  Humoral autoreactivity directed against surfactant protein-A (SP-A) in rheumatoid arthritis synovial fluids.

Authors:  P K Trinder; T P Hickling; R B Sim; D Brackertz; M Loos; M J Maeurer
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

5.  Hypocomplementemic urticarial vasculitis syndrome: a case report and literature review.

Authors:  Andrew Buck; Jim Christensen; Morgan McCarty
Journal:  J Clin Aesthet Dermatol       Date:  2012-01

Review 6.  Urticarial vasculitis.

Authors:  Joe Venzor; Wai L Lee; David P Huston
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

7.  Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN).

Authors:  H Ohi; T Yasugi
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

8.  Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus.

Authors:  C E Siegert; M R Daha; C M Tseng; I E Coremans; L A van Es; F C Breedveld
Journal:  Ann Rheum Dis       Date:  1993-12       Impact factor: 19.103

9.  Serologic markers of lupus nephritis in patients: use of a tissue-based ELISA and evidence for immunopathogenic heterogeneity.

Authors:  K A Bernstein; L E Kahl; J E Balow; J B Lefkowith
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

10.  IgG autoantibodies to C1q do not detectably influence complement activation in vivo and in vitro in systemic lupus erythematosus.

Authors:  C E Siegert; M R Daha; S Lobatto; E A van der Voort; F C Breedveld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.